Résumé
Recently, osteoporosis is regarded as a major health concern due to increase in its incidence, associated morbidities and mortalities. Among antiresorptives, alendronate which is a bisphosphonate is FDA [Food and Drug Administration] approved drug of choice for postmenopausal and glucorticoid induced osteoporosis. It has been also recommended for the prevention of bone loss in perimenopausal women. Currently, it has been also viewed as a treatment option in osteoporotic males. Several clinical trials have highlighted the significant role of alendronate in the management of osteoporosis. Although it was proved to be a safe drug for long time periods but very recently some studies have reported the risk of low energy subtrochanteric and diaphyseal femoral shaft fractures in the chronic users of alendronate. The current review is undertaken to elaborate the different aspects related to this drug in the scenario of osteoporosis management